sirna

Type: Keyphrase
Name: sirna
First reported Apr 19 2014 - Updated Apr 19 2014 - 1 reports

Dioctadecyldimethylammonium:Monoolein Nanocarriers for Efficient in Vitro Gene Silencing

This study describes a novel liposomal formulation for siRNA delivery, based on the mixture of the neutral lipid monoolein (MO) and cationic lipids of the dioctadecyldimethylammonium (DODA) family. The cationic lipids dioctadecyldimethylammonium bromide ... [Published ACS Applied Materials & Interfaces - Apr 19 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Reports from Pfizer Add New Data to Findings in Small Interference RNAs (siRNAs)

(NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on Small Interference RNAs (siRNAs). According to news originating from San Diego, California, by NewsRx correspondents, research stated, "The ... [Published NewsRX - Apr 18 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 1 reports

Dicerna Pharmaceuticals Initiates Phase 1 Study Of DCR-MYC In Patients With Solid Tumors And Hematological Malignancies

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the initiation of a Phase 1 dose-escalating clinical study of DCR-MYC, (also known as DCR-M1711), in patients with solid tumors, multiple ... [Published TheStreet.com - Apr 16 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Prolongation of Life in Rats with Malignant Glioma by Intranasal siRNA/Drug Codelivery to the Brain with Cell-Penetrating Peptide-Modified Micelles

New therapeutic strategies are required to develop candidate drugs and ensure efficient delivery of these drugs to the brain and the central nervous system (CNS). Small interfering RNA (siRNA)-based therapies have been investigated as potential novel ... [Published Molecular Pharmaceutics - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Findings from University of Coimbra Reveals New Findings on Cancer Gene Therapy

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news originating from Coimbra , Portugal , by NewsRx correspondents, research stated, "The identification of numerous deregulated ... [Published HispanicBusiness.com - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Studies from University of Louisville Describe New Findings in Gene Therapy

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A new study on Biotechnology is now available. According to news reporting originating from Louisville, Kentucky , by NewsRx correspondents, research stated, "Prostate cancer (PCa) often shows ... [Published HispanicBusiness.com - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Reports from Pfizer Add New Data to Findings in Small Interference RNAs (siRNAs)

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on Small Interference RNAs (siRNAs). According to news originating from San Diego, California , by NewsRx correspondents, research stated, "The intraocular ... [Published 4 Traders - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Researchers from Delaware Biotechnology Institute Report Recent Findings in General Science

By a News Reporter-Staff News Editor at Agriculture Week -- Investigators publish new report on Science. According to news reporting from Newark, Delaware , by VerticalNews journalists, research stated, "Transposable elements (TEs) and repetitive sequences ... [Published HispanicBusiness.com - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Patent Issued for Oligonucleotides for Modulating Target RNA Activity

By a News Reporter-Staff News Editor at Clinical Trials Week -- According to news reporting originating from Alexandria, Virginia , by NewsRx journalists, a patent by the inventor Moller , Thorleif (Linhamn, SE), filed on June 13, 2008 , was published ... [Published 4 Traders - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

NOVARTIS : Researchers Submit Patent Application, "RNAi INHIBITION OF CTGF FOR TREATMENT OF OCULAR DISORDERS", for Approval

By a News Reporter-Staff News Editor at Diabetes Week -- From Washington, D.C. , NewsRx journalists report that a patent application by the inventors Shepard, Allan R. ( Fort Worth, TX ); Pang, lok-Hou ( Grand Prairie, TX ), filed on December 5, 2013 ... [Published 4 Traders - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Correction for Dong et al., Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates [Correction]

ENGINEERING Correction for “Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates,” by YizhouDong, Kevin T. Love, J. Robert Dorkin, Sasilada Sirirungruang, Yunlong Zhang, Delai Chen, Roman L. Bogorad, Hao Yin, ... [Published PNAS - Apr 15 2014]
Entities: sirna, Nanoparticle, Yi Chen
First reported Apr 14 2014 - Updated Apr 15 2014 - 3 reports

Why Alnylam Pharmaceuticals (ALNY) Stock is Down Today

NEW YORK (TheStreet) -- Alnylam Pharmaceuticals  dipped Monday amid reports that Novartis  is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems ... [Published The Street Latest - Apr 14 2014]

Quotes

...reclinical studies, DCR-MYC demonstrated impressive knockdown of the MYC oncogene," stated Pankaj Bhargava , M D , Chief Medical Officer of Dicerna. "The PhasePhase 1 trial of DCR-MYC now provides us the opportunity to test these promising data in clinical trials, furthering our efforts to realize the significant therapeutic potential of Dicer Substrate RNARNA interference."
" If a biotech owns a platform technology, it is much easier to build a robust pipeline in a cost-effective way."
...According to news originating from San Diego, California, by NewsRx correspondents, research stated, "The intraocular pharmacodynamics of PF-04523655, a small-interfering RNA (siRNA) directed against RTP801, was characterized using rat models of retinopathy. Rat models of streptozotocin-induced diabetes and wet AMD were used to determine the onset, extent, and duration of siRNA inhibition of retinal RTP801 expression by PF-04523655, and this inhibition was characterized by pharmacokinetic/pharmacodynamic (PK/PD)... We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3."
According to the news editors, the research concluded: "AML-M2 can feasibly be treated by target-inhibiting HO-1 that enhances the antileukemia effects of UA in vitro and in vivo."

More Content

All (245) | News (228) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
DICERNA PHARMACEUTICALS : Begins Phase 1 Study ... [Published 4 Traders - 2 hours ago]
Methods and compositions for treating brain dis... [Published PharmCast - 9 hours ago]
Molecular Mechanisms of Cadmium-Induced Fibrobl... [Published Toxicological Sciences - 19 hours ago]
Ċelebrazzjoni tal-Unjoni Ċivili [Published MaltaToday - Apr 19 2014]
Dioctadecyldimethylammonium:Monoolein Nanocarr... [Published ACS Applied Materials & Interfaces - Apr 19 2014]
CD44 variant 6 is associated with prostate canc... [Published UroToday - Apr 18 2014]
Organ Preservation Solutions Market - Global In... [Published Michigan Live - Apr 18 2014]
Build Biotech Wealth on Solid Platforms: Grant ... [Published Stockboard Media Inc. - Apr 18 2014]
Reports from Pfizer Add New Data to Findings in... [Published NewsRX - Apr 18 2014]
Art27 Interacts with GATA4, FOG2 and NKX2.5 and... [Published PLoS medicine - Apr 17 2014]
Soluble CEACAM8 Interacts with CEACAM1 Inhibiti... [Published PLoS medicine - Apr 17 2014]
Foxm1 Mediates LIF/Stat3-Dependent Self-Renewal... [Published PLoS medicine - Apr 17 2014]
miR-375 activates p21 and suppresses telomerase... [Published MOLECULAR CANCER - Apr 17 2014]
Reports from D. Ma and Colleagues Advance Knowl... [Published 4 Traders - Apr 17 2014]
Prolongation of Life in Rats with Malignant Gli... [Published Molecular Pharmaceutics - Apr 17 2014]
Patent Issued for Methods and Compositions for ... [Published 4 Traders - Apr 17 2014]
Investigators from Eastman Dental Institute Tar... [Published HispanicBusiness.com - Apr 17 2014]
New Findings in Cancer Gene Therapy Described f... [Published HispanicBusiness.com - Apr 16 2014]
Studies from University of Louisville Describe ... [Published HispanicBusiness.com - Apr 16 2014]
Findings from University of Coimbra Reveals New... [Published HispanicBusiness.com - Apr 16 2014]
Patent Issued for Methods and Compositions for ... [Published HispanicBusiness.com - Apr 16 2014]
Don't Miss the Boat on Big Biotech Catalysts: K... [Published Equities.com - Apr 16 2014]
Reports from Pfizer Add New Data to Findings in... [Published 4 Traders - Apr 16 2014]
Researchers from Delaware Biotechnology Institu... [Published HispanicBusiness.com - Apr 16 2014]
Dicerna Pharmaceuticals Initiates Phase 1 Study... [Published Benzinga.com - Apr 16 2014]
Dicerna Pharmaceuticals Initiates Phase 1 Study... [Published TheStreet.com - Apr 16 2014]
Dicerna Pharmaceuticals Initiates Phase 1 Study... [Published Business Wire Health News - Apr 16 2014]
Patent Issued for Oligonucleotides for Modulati... [Published 4 Traders - Apr 16 2014]
NOVARTIS : Researchers Submit Patent Applicatio... [Published 4 Traders - Apr 16 2014]
Caspase-11 activation requires lysis of pathoge... [Published Free Internet Press - Apr 16 2014]
1 2 3 4 5 6 7 8 9
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Dicerna Pharmaceuticals Initiates Phase 1 Study... [Published Business Wire Health News - Apr 16 2014]
WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the initiation of a Phase 1 dose-escalating clinical study of DCR-MYC, (also known as DCR-M1711), ...
Alnylam’s McSwiggen Patent Upheld in European O... [Published Business Wire Health News - Apr 07 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has upheld the McSwiggen EP 1423406 (’406) patent in oral opposition proceedings ...
Ensysce Biosciences Inc. Receives Notice of All... [Published Business Wire Health News - Mar 06 2014]
HOUSTON--(BUSINESS WIRE)--Ensysce Biosciences Inc. announced today that the U.S. Patent Office has issued a Notice of Allowance for U.S. Patent Application No. 13/175,314: SINGLE-WALLED CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO. The ...
Ensysce Biosciences Inc. Receives Notice of All... [Published Business Wire Technology News - Mar 06 2014]
HOUSTON--(BUSINESS WIRE)--Ensysce Biosciences Inc. announced today that the U.S. Patent Office has issued a Notice of Allowance for U.S. Patent Application No. 13/175,314: SINGLE-WALLED CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO. The ...
Alnylam Announces Closing of Previously Announc... [Published EON Science - Mar 06 2014]
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the previously announced acquisition of Merck’s wholly owned subsidiary Sirna Therapeutics, Inc. (“Sirna ...
1 2 3

Press Releases

sort by: Date | Relevance
Global Huntington%s Disease Therapeutics Industry [Published PR Newswire - Aug 07 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.